Assess whether a CMC change is a comparability or a new product (44e75e)

Situation

The desk packet is scientific-advice briefing book after an AdCom briefing document that overstates subgroup findings. Pharmacovigilance medical reviewer in a safety team sitting on a new disproportionate signal has to name A CMC change is a comparability or A new product for this Pharma & Life Sciences FDA Response and Labeling file.

Decision

Pharmacovigilance medical reviewer in a safety team sitting on a new disproportionate signal must choose A CMC change is a comparability / A new product using scientific-advice briefing book after an AdCom briefing document that overstates subgroup findings.

Hypotheses to test

• The population in scientific-advice briefing book is the one an AdCom briefing document that overstates subgroup findings named, so A CMC change is a comparability follows for this FDA Response and Labeling file.
• The population in scientific-advice briefing book is adjacent only to an AdCom briefing document that overstates subgroup findings; A new product is the honest Pharma & Life Sciences call.
• A safety team sitting on a new disproportionate signal already contained an AdCom briefing document that overstates subgroup findings before scientific-advice briefing book arrived; no new FDA Response and Labeling path.
• Provenance on scientific-advice briefing book after an AdCom briefing document that overstates subgroup findings is broken; do not pick A CMC change is a comparability or A new product yet.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on a CMC change is.
• Check whether scientific-advice briefing book supports the labeled claim pharmacovigilance medical reviewer would keep.
• Map FDA-response timing and owner in a safety team sitting on a new disproportionate signal.
• For this Pharma & Life Sciences FDA Response and Labeling file, read scientific-advice briefing book against an AdCom briefing document that overstates subgroup findings and write the one fact that would move a CMC change is for pharmacovigilance medical reviewer.

Recommendation

Choose A CMC change is a comparability / A new product on this Pharma & Life Sciences / FDA Response and Labeling packet (scientific-advice briefing book after an AdCom briefing document that overstates subgroup findings). Lead with the Pharma & Life Sciences option scientific-advice briefing book can support after an AdCom briefing document that overstates subgroup findings, then the two facts that force it, then the Monday action for pharmacovigilance medical reviewer in a safety team sitting on a new disproportionate signal.